SCHEMBL19902484

SCHEMBL19902484

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cc2ccc(Cl)cc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.46
F10 P00742 2/20 0.45
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
KMT2A Q03164 2/20 0.41
DHPS P49366 1/20 0.41
THRB P10828 1/20 0.41
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41
PRSS12 P56730 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
KDR P35968 1/20 0.39
PLK1 P53350 1/20 0.39
CCNA1 P78396 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452839 0.89 ROCK2 (0.51) CHRNA7F10RAB9ANPC1CCNC
SCHEMBL19902482 0.78 SMYD3 (0.45) NPC1KMT2AL3MBTL1MEN1ROCK2
SCHEMBL19902364 0.78 RAB9A (0.44) RAB9ANPC1KMT2ATHRBL3MBTL1
SCHEMBL8306899 0.74 CHRNA7 (0.58) CHRNA7F10RAB9ANPC1KMT2A
SCHEMBL19902631 0.74 HDAC8 (0.42) RAB9ANPC1HTR1ADRD2KDM4E
SCHEMBL19902689 0.73 ROCK2 (0.46) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL19902711 0.73 PYGL (0.48) ROCK2ROCK1
SCHEMBL19902356 0.73 CHRNA7 (0.45) CHRNA7RAB9ANPC1ALDH1A1ROCK2
SCHEMBL19902458 0.73 SCN4A (0.48) CHRNA7NPC1KMT2AHTR1ADRD2
SCHEMBL19902580 0.73 HPGDS (0.42) RAB9ANPC1KMT2AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 CHRNA7 1851/4885F10 4353/4885RAB9A 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.